Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Exploring Long-Term Outcomes of Tildrakizumab in PsA

home / post-conference-perspectives / exploring-long-term-outcomes-of-tildrakizumab-in-psa

1 expert is featured in this series.

EP. 1: Sustained Safety Tildrakizumab for Psoriatic Arthritis

Christopher Ritchlin, MD, MPH

December 10th 2025

Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis.

Watch

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences
AJMC®
All rights reserved.